Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease

BACKGROUND: Clinicians often utilize off-label dose escalation of ustekinumab (UST) in Crohn’s disease (CD) patients with disease refractory to standard dosing. Previous studies report mixed results with dose escalation of UST. METHODS: A retrospective observational study of 143 adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Syedreza A., Yadav, Abhijeet, Perry, Courtney, Su, Leon, Akanbi, Olalekan, Kudaravalli, Praneeth, Tripathi, Nishant, Hashim, Mahmoud A., Abdelsalam, Mohammed, Hussein, Mohamed, Elkheshen, Ahmed, Patel, Vihang, Ali, Saad Emhmed, Lamb, Latoya, Ingram, Karen, Mayne, Casie, Stuffelbeam, Amy B., Flomenhoft, Deborah, Stromberg, Arnold, Barrett, Terrence A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576911/
https://www.ncbi.nlm.nih.gov/pubmed/33133239
http://dx.doi.org/10.1177/1756284820959245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576911/
https://www.ncbi.nlm.nih.gov/pubmed/33133239
http://dx.doi.org/10.1177/1756284820959245

Ejemplares similares